The PwC report also outlines potential ways by which pharmaceutical companies can restructure their supply chains.
Therapy companies, for instance, may outsource all manufacturing, warehousing and distribution operations. They may also build supply chains where they can manufacture and distribute their own treatments, as well as partner with alternative healthcare providers.
Drug manufacturers may implement strategies in lean manufacturing, strategic pricing and inventory management to mass produce drugs and warehouse supplies that can be sold at lower prices. Mass producers may also incorporate add-on services such as door-to-door deliveries in their supply chains.
About PwC
PricewaterhouseCoopers provides assurance, tax and business consulting services. PwC is a Delaware limited liability partnership and a member firm of PricewaterhouseCoopers International Limited. The company has offices in 154 countries and boasts a workforce of 161,000 expert consultants.
The PwC report is the latest in the Pharma 2020 series, Supplying the Future: Which path will you take? The report is available for download at https://www.pwc.com/pharma2020supplychain.